Alkermes plc (Nasdaq:ALKS) announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study.Alkermes Plc (NASDAQ:ALKS) shares after opening at $44.21 moved to $45.48 on last trade day and at the end of the day closed at $42.08. Company price to sales ratio in past twelve months was calculated as 10.17 and price to cash ratio as 16.75. Alkermes Plc (NASDAQ:ALKS) showed a negative weekly performance of -6.96%.
For the purposes of familiarity, RadNet Inc. (NASDAQ:RDNT) is a diagnostic imaging company. This $154 million company owns about 250 imaging facilities which are spread in seven states.The stock has been in a decent rally of late, but as they say, all things with a beginning have their end. That is to say that good things might just be about to come to an end at RadNet. But this claim is better explained.RadNet Inc. (NASDAQ:RDNT) shares advanced 9.84% in last trading session and ended the day on $4.13. RDNT its return on assets is 0.30%. RadNet Inc. (NASDAQ:RDNT) yearly performance is 49.64%.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) announced that it has entered into subscription agreements with institutional and accredited investors for the sale of its common stock in a registered direct offering. The Company is selling 1.8 million shares of common stock at a price of $10.00 per share, for gross proceeds of approximately $18 million. Chardan Capital Markets, LLC acted as lead placement agent and Brean Capital, LLC acted as co-placement agent for the offering. The sale and issuance of the shares is expected to close on or about April 11, 2014OHR Pharmaceutical Inc (NASDAQ:OHRP) shares moved down -18.20% in last trading session and was closed at $9.84, while trading in range of $9.70-$10.57. OHR Pharmaceutical Inc (NASDAQ:OHRP) year to date performance is 24.87%.
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART®) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.MacroGenics Inc (NASDAQ:MGNX) weekly performance is -20.74%. On last trading day company shares ended up $23.24. MacroGenics Inc (NASDAQ:MGNX) distance from 50-day simple moving average is -32.57%. Analysts mean target price for the company is $56.25.